Mylotarg, also known as gemtuzumab ozogamicin, is a medication used in the treatment of acute myeloid leukemia (AML). AML is a type of cancer that affects the bone marrow and blood cells, and Mylotarg works by targeting and destroying cancer cells in the body.

This medication is typically used in combination with other chemotherapy drugs to improve outcomes for patients with AML. It is administered intravenously by a healthcare provider in a clinical setting, and the dosage and frequency of treatment will be determined by your healthcare team based on your individual condition and response to the medication.

As with any medication, Mylotarg may cause side effects. Common side effects include nausea, vomiting, fatigue, and low blood cell counts. It is important to discuss any side effects you experience with your healthcare provider, as they may be able to provide support or adjust your treatment plan to help manage these symptoms.

It is important to follow your healthcare provider’s instructions carefully while taking Mylotarg. This medication has been shown to be effective in treating AML, but it is important to take it as prescribed to achieve the best possible outcomes.

If you have any questions or concerns about Mylotarg or your treatment plan, do not hesitate to reach out to your healthcare provider. They are there to support you and help you navigate your treatment journey. Remember, you are not alone in this fight against cancer, and there are resources and support available to help you every step of the way.